Breast Cancer and HER2-low Disease
Dualitybio Inc. is involved in clinical research for metastatic breast cancer, with a focus on hormone receptor positive and HER2-low disease. Its studies address treatment needs in patients with advanced breast tumors where HER2 expression is low and targeted options remain limited.
- Hormone receptor positive breast cancer
- HER2-low metastatic breast cancer
- Progression-free survival
The research portfolio in this area reflects interest in therapeutic strategies for advanced breast cancer and biomarker-defined patient groups.
Advanced Solid Tumors
The sponsor is also active in studies of advanced and metastatic solid tumors, including cancers with high unmet medical need across multiple tumor types.
- Metastatic solid tumors
- Combination oncology therapy
- Targeted cancer treatment
This area includes treatment development for diverse solid malignancies in both locally advanced and disseminated settings.
Gynecologic Malignancies
Dualitybio Inc. has research interests in cervical cancer and ovarian cancer, supporting investigation in gynecologic oncology where durable disease control remains a major clinical goal.
- Cervical cancer
- Ovarian cancer
- Gynecologic oncology
These programs indicate attention to tumor types with significant burden in advanced and recurrent disease.
Gastrointestinal and Liver Cancer
The sponsor funds research in hepatocellular carcinoma, a major liver cancer indication that requires effective systemic treatment options.
- Hepatocellular carcinoma
- Liver cancer
- Oncology drug development
This focus extends the company’s oncology portfolio into cancers driven by distinct biological and clinical challenges.
Thoracic and Head and Neck Oncology
Its trial activity also includes non-small cell lung cancer, melanoma, and squamous cell carcinoma of the head and neck, covering several difficult-to-treat malignancies across thoracic, skin, and head and neck cancer settings.
- Non-small cell lung cancer
- Melanoma
- Squamous cell carcinoma of the head and neck
These disease areas broaden the sponsor’s oncology interests across both common and aggressive cancer subtypes.
